Study: Public clueless about cost of drug development; Bristol-Myers recalls brain tumor drug;

 @FiercePharma: Judge won't let Pfizer rid itself of inherited fen-phen scourge. Story | Follow @FiercePharma

> The FDA has issued a warning against the off-label use of Pfizer's ($PFE) pulmonary arterial hypertension (PAH) drug Revatio in children up to 17. Story 

> A new study in the U.K. finds that the public has no idea how much it costs drugmakers to develop medications or just how little the health service pays for them. Release

> Bristol-Myers Squibb ($BMY) is recalling more than 31,000 units of a chemotherapy drug BiCNU for brain tumors after discovering one vial was overfilled. Story 

> A new study finds that although hormone usage can help women dampen the symptoms of menopause, the number of women that do use hormones has continued to decline since the 2002 watershed study finding risks. Item

Medical Device News

 @FierceMedDev: A new Abbott-related study backs up kidney stenting to lower blood pressure in patients with severe hypertension. Release | Follow @FierceMedDev

 @MarkHFierce: Another day, another lawsuit filed over DePuy's ASR metal-on-metal hip implant. More | Follow @MarkHFierce

 @DamianFierce: St. Jude is axing 300 employees and reorganizing its business units in a plan to save about $60M a year. More | Follow @DamianFierce

> As vascular procedures move out of hospitals, devicemakers must adjust. Story

> Acutus Medical attracts $2.5M for cardiac arrhythmia Dx development. Item

Biotech News

 @FierceBiotech: Johns Hopkins scientists produce protein that helps track tumors. Story | Follow @FierceBiotech

 @JohnCFierce: Bellwether? IBA chief says plunge in bioassay sales in Europe reflects freeze in research activities. Report | Follow @JohnCFierce

 @RyanMFierce: Matching brain scan data with psych drugs helps improve doctor's educated guessing in prescribing depression meds. Article | Follow @RyanMFierce

> Pfizer licenses out cancer candidate to biotech VLST. Item

> FDA scrutinizes efficacy of Novartis' cystic fibrosis drug. Story

> Achillion Pharma strikes deal to raise $41.8M as hep C results loom. News

> EU hits accelerator on Ariad's leukemia drug app. Article

> Report precedes stock jump for biotech Sarepta. More

And Finally... IBA says its bioassay testing products have nearly ground to a halt as buyers like Sanofi ($SNY) have dramatically cut R&D spending. Story

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.